Disturbed mitochondrial dynamics and neurodegenerative disorders

Nature Reviews Neurology

Volumn 11, Issue 1, 2015, Pages 11-24

  Burté, Florence ^a   Carelli, Valerio ^b   Chinnery, Patrick F ^a   Yu Wai Man, Patrick ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b BELLARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IDEBENONE; MITOFUSIN 1; OPTIC ATROPHY 1; PARVOVIRUS VECTOR; PROTEIN; UNCLASSIFIED DRUG; VATIQUINONE;

ALZHEIMER DISEASE; APOPTOSIS; DEGENERATIVE DISEASE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; LEBER HEREDITARY OPTIC NEUROPATHY; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL FISSION; MITOCHONDRIAL FUSION; MITOCHONDRION; MITOPHAGY; MUTATION; NERVE FIBER; NONHUMAN; ONSET AGE; OPTIC NERVE ATROPHY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RESPIRATORY CHAIN; REVIEW; GENETICS; METABOLISM;

HUMANS; MITOCHONDRIA; MITOCHONDRIAL DYNAMICS; NEURODEGENERATIVE DISEASES;

EID: 84926258887     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.228     Document Type: Review

References (227)

1. Chan, D. C. Mitochondria: dynamic organelles in disease, aging, and development. Cell 125, 1241-1252 (2006).
2. Yu-Wai-Man, P., Griffiths, P. G., Hudson, G. & Chinnery, P. F. Inherited mitochondrial optic neuropathies. J. Med. Genet. 46, 145-158 (2009).
3. 8th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Neuromuscul. Disord. 20, 839-846 (2010).
4. Saporta, A. S. D. et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann. Neurol. 69, 22-33 (2011).
5. Yu-Wai-Man, P., Lenaers, G. & Chinnery, P. F. in Mitochondrial Disorders Caused by Nuclear Genes (ed. Wong, L.-J.C.) 141-161 (Springer, 2013).
6. Belenguer, P. & Pellegrini, L. The dynamin GTPase OPA1: more than mitochondria? Biochim. Biophys. Acta 1833, 176-183 (2013).
7. Chen, H. C. et al. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J. Cell Biol. 160, 189-200 (2003).
8. Eura, Y., Ishihara, N., Yokota, S. & Mihara, K. Two mitofusin proteins, mammalian homologues of FZO, with distinct functions are both required for mitochondrial fusion. J. Biochem. 134, 333-344 (2003).
9. Lenaers, G. et al. OPA1 functions in mitochondria and dysfunctions in optic nerve. Int. J. Biochem. Cell Biol. 41, 1866-1874 (2009).
10. Frezza, C. et al. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 126, 177-189 (2006).
11. Amati-Bonneau, P. et al. OPA1 R445H mutation in optic atrophy associated with sensorineural deafness. Ann. Neurol. 58, 958-963 (2005).
12. Zanna, C. et al. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain 131, 352-367 (2008).
13. Loson, O. C., Song, Z., Chen, H. & Chan, D. C. Fis1, Mff, MiD49, and MiD51 mediate Drp1 recruitment in mitochondrial fission. Mol. Biol. Cell 24, 659-667 (2013).
14. Rostovtseva, T. K. et al. Bax activates endophilin B1 oligomerization and lipid membrane vesiculation. J. Biol. Chem. 284, 34390-34399 (2009).
15. Tondera, D. et al. The mitochondrial protein MTP18 contributes to mitochondrial fission in mammalian cells. J. Cell Sci. 118, 3049-3059 (2005).
16. Takahashi, Y., Meyerkord, C. L. & Wang, H. G. Bif-1/endophilin B1: a candidate for crescent driving force in autophagy. Cell Death Differ. 16, 947-955 (2009).
17. Olichon, A. et al. The human dynamin-related protein OPA1 is anchored to the mitochondrial inner membrane facing the inter-membrane space. FEBS Lett. 523, 171-176 (2002).
18. Olichon, A. et al. OPA1 alternate splicing uncouples an evolutionary conserved function in mitochondrial fusion from a vertebrate restricted function in apoptosis. Cell Death Differ. 14, 682-692 (2007).
19. Duvezin-Caubet, S. et al. OPA1 processing reconstituted in yeast depends on the subunit composition of the m-AAA protease in mitochondria. Mol. Biol. Cell 18, 3582-3590 (2007).
20. Martinelli, P. & Rugarli, E. I. Emerging roles of mitochondrial proteases in neurodegeneration. Biochim. Biophys. Acta 1797, 1-10 (2010).
21. Ishihara, N., Fujita, Y., Oka, T. & Mihara, K. Regulation of mitochondrial morphology through proteolytic cleavage of OPA1. EMBO J. 25, 2966-2977 (2006).
22. Griparic, L., Kanazawa, T. & van der Bliek, A. M. Regulation of the mitochondrial dynamin-like protein Opa1 by proteolytic cleavage. J. Cell Biol. 178, 757-764 (2007).
23. Song, Z., Chen, H., Fiket, M., Alexander, C. & Chan, D. C. OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and Yme1L. J. Cell Biol. 178, 749-755 (2007).
24. McQuibban, G. A., Saurya, S. & Freeman, M. Mitochondrial membrane remodelling regulated by a conserved rhomboid protease. Nature 423, 537-541 (2003).
25. Cipolat, S. et al. Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis via OPA1-dependent cristae remodeling. Cell 126, 163-175 (2006).
26. Ehses, S. et al. Regulation of OPA1 processing and mitochondrial fusion by m-AAA protease isoenzymes and OMA1. J. Cell Biol. 187, 1023-1036 (2009).
27. Head, B., Griparic, L., Amiri, M., Gandre- Babbe, S. & van der Bliek, A. M. Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cells. J. Cell Biol. 187, 959-966 (2009).
28. Mishra, P., Carelli, V., Manfredi, G. & Chan, D. C. Proteolytic cleavage of Opa1 stimulates mitochondrial inner membrane fusion and couples fusion to oxidative phosphorylation. Cell Metab. 19, 630-641 (2014).
29. Pich, S. et al. The Charcot-Marie-Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system. Hum. Mol. Genet. 14, 1405-1415 (2005).
30. Agier, V. et al. Defective mitochondrial fusion, altered respiratory function, and distorted cristae structure in skin fibroblasts with heterozygous OPA1 mutations. Biochim. Biophys. Acta 1822, 1570-1580 (2012).
31. Chevrollier, A. et al. Hereditary optic neuropathies share a common mitochondrial coupling defect. Ann. Neurol. 63, 794-798 (2008).
32. Cogliati, S. et al. Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency. Cell 155, 160-171 (2013).
33. Lodi, R. et al. Deficit of in vivo mitochondrial ATP production in OPA1-related dominant optic atrophy. Ann. Neurol. 56, 719-723 (2004).
34. Lodi, R. et al. Defective mitochondrial adenosine triphosphate production in skeletal muscle from patients with dominant optic atrophy due to OPA1 mutations. Arch. Neurol. 68, 67-73 (2011).
35. Yu-Wai-Man, P., Trenell, M. I., Hollingsworth, K. G., Griffiths, P. G. & Chinnery, P. F. OPA1 mutations impair mitochondrial function in both pure and complicated dominant optic atrophy. Brain 134, e164 (2011).
36. Del Bo, R. et al. Mutated mitofusin 2 presents with intrafamilial variability and brain mitochondrial dysfunction. Neurology 71, 1959-1966 (2008).
37. Area-Gomez, E. et al. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J. 31, 4106-4123 (2012).
38. de Brito, O. M. & Scorrano, L. An intimate liaison: spatial organization of the endoplasmic reticulum-mitochondria relationship. EMBO J. 29, 2715-2723 (2010).
39. Kornmann, B. et al. An ER-mitochondria tethering complex revealed by a synthetic biology screen. Science 325, 477-481 (2009).
40. Merkwirth, C. & Langer, T. Mitofusin 2 builds a bridge between ER and mitochondria. Cell 135, 1165-1167 (2008).
41. Lam, A. K. M. & Galione, A. The endoplasmic reticulum and junctional membrane communication during calcium signaling. Biochim. Biophys. Acta 1833, 2542-2559 (2013).
42. 2+ uniporter by exerting opposite effects on MCU activity. Mol. Cell 53, 726-737 (2014).
43. Baughman, J. M. et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature 476, 341-345 (2011).
44. 2+ uptake. Nature 467, 291-296 (2010).
45. 2+ uniporter. Cell Metab. 17, 976-987 (2013).
46. Logan, C. V. et al. Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary alterations in mitochondrial calcium signaling. Nat. Genet. 46, 188-193 (2014).
47. 2+ clearance. Ophthalmic Genet. 31, 53-65 (2010).
48. Kushnareva, Y. E. et al. Loss of OPA1 disturbs cellular calcium homeostasis and sensitizes for excitotoxicity. Cell Death Differ. 20, 353-365 (2013).
49. 2+ store to the plasma membrane in cells with depolarized mitochondria. J. Biol. Chem. 286, 12189-12201 (2011).
50. de Brito, O. M. & Scorrano, L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 456, 605-611 (2008).
51. Friedman, J. R. et al. ER tubules mark sites of mitochondrial division. Science 334, 358-362 (2011).
52. Hayashi, T., Rizzuto, R., Hajnoczky, G. & Su, T.-P. MAM: more than just a housekeeper. Trends Cell Biol. 19, 81-88 (2009).
53. Schon, E. A. & Przedborski, S. Mitochondria: the next (neurode) generation. Neuron 70, 1033-1053 (2011).
54. Arnoult, D. Mitochondrial fragmentation in apoptosis. Trends Cell Biol. 17, 6-12 (2007).
55. Suen, D. F., Norris, K. L. & Youle, R. J. Mitochondrial dynamics and apoptosis. Genes Dev. 22, 1577-1590 (2008).
56. Levine, B., Sinha, S. & Kroemer, G. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 4, 600-606 (2008).
57. Renault, T. T. & Manon, S. Bax: addressed to kill. Biochimie 93, 1379-1391 (2011).
58. Walensky, L. D. & Gavathiotis, E. BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem. Sci. 36, 642-652 (2011).
59. Ekert, P. G. & Vaux, D. L. The mitochondrial death squad: hardened killers or innocent bystanders? Curr. Opin. Cell Biol. 17, 626-630 (2005).
60. Scorrano, L. et al. A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. Dev. Cell 2, 55-67 (2002).
61. Olichon, A. et al. Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J. Biol. Chem. 278, 7743-7746 (2003).
62. Arnoult, D., Grodet, A., Lee, Y. J., Estaquier, J. & Blackstone, C. Release of OPA1 during apoptosis participates in the rapid and complete release of cytochrome c and subsequent mitochondrial fragmentation. J. Biol. Chem. 280, 35742-35750 (2005).
63. Karbowski, M., Norris, K. L., Cleland, M. M., Jeong, S.-Y. & Youle, R. J. Role of Bax and Bak in mitochondrial morphogenesis. Nature 443, 658-662 (2006).
64. Neuspiel, M., Zunino, R., Gangaraju, S., Rippstein, P. & McBride, H. Activated mitofusin 2 signals mitochondrial fusion, interferes with Bax activation, and reduces susceptibility to radical induced depolarization. J. Biol. Chem. 280, 25060-25070 (2005).
65. Chinnery, P. F., Samuels, D. C., Elson, J. & Turnbull, D. M. Accumulation of mitochondrial DNA mutations in ageing, cancer, and mitochondrial disease: is there a common mechanism? Lancet 360, 1323-1325 (2002).
66. Rugarli, E. I. & Langer, T. Mitochondrial quality control: a matter of life and death for neurons. EMBO J. 31, 1336-1349 (2012).
67. Twig, G. & Shirihai, O. S. The interplay between mitochondrial dynamics and mitophagy. Antioxid. Redox Signal. 14, 1939-1951 (2011).
68. Twig, G., Hyde, B. & Shirihai, O. S. Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view. Biochim. Biophys. Acta 1777, 1092-1097 (2008).
69. Twig, G. et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J. 27, 433-446 (2008).
70. Youle, R. J. & van der Bliek, A. M. Mitochondrial fission, fusion, and stress. Science 337, 1062-1065 (2012).
71. Gegg, M. E. et al. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum. Mol. Genet. 19, 4861-4870 (2010).
72. Matsuda, N. et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell Biol. 189, 211-221 (2010).
73. Narendra, D., Tanaka, A., Suen, D.-F. & Youle, R. J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795-803 (2008).
74. Pallanck, L. Mitophagy: mitofusin recruits a mitochondrial killer. Curr. Biol. 23, R570-R572 (2013).
75. Chen, Y. & Dorn, G. W. 2nd. PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science 340, 471-475 (2013).
76. Kane, L. A. & Youle, R. J. PINK1 and Parkin flag Miro to direct mitochondrial traffic. Cell 147, 721-723 (2011).
77. Shin, J. H. et al. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell 144, 689-702 (2011).
78. Mueller-Rischart, A. K. et al. The E3 ligase Parkin maintains mitochondrial integrity by increasing linear ubiquitination of NEMO. Mol. Cell 49, 908-921 (2013).
79. Liu, S. et al. Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genet. 8, e1002537 (2012).
80. Wang, X. et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 147, 893-906 (2011).
81. Sterky, F. H., Lee, S., Wibom, R., Olson, L. & Larsson, N.G. Impaired mitochondrial transport and Parkin-independent degeneration of respiratory chain-deficient dopamine neurons in vivo. Proc. Natl Acad. Sci. USA 108, 12937-12942 (2011).
82. Yu-Wai-Man, P. et al. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmology 117, 1538-1546 (2010).
83. Yu-Wai-Man, P. & Chinnery, P. F. Dominant optic atrophy: novel OPA1 mutations and revised prevalence estimates. Ophthalmology 120, 1712-1712.e1 (2013).
84. Yu-Wai-Man, P., Bailie, M., Atawan, A., Chinnery, P. F. & Griffiths, P. G. Pattern of retinal ganglion cell loss in dominant optic atrophy due to OPA1 mutations. Eye 25, 597-601 (2011).
85. Cohn, A. C. et al. The natural history of OPA1- related autosomal dominant optic atrophy. Br. J. Ophthalmol. 92, 1333-1336 (2008).
86. Yu-Wai-Man, P. et al. Genetic screening for OPA1 and OPA3 mutations in patients with suspected inherited optic neuropathies. Ophthalmology 118, 558-563 (2011).
87. Votruba, M., Moore, A. T. & Bhattacharya, S. S. Clinical features, molecular genetics, and pathophysiology of dominant optic atrophy. J. Med. Genet. 35, 793-800 (1998).
88. Bailie, M., Votruba, M., Griffiths, P. G., Chinnery, P. F. & Yu-Wai-Man, P. Visual and psychological morbidity among patients with autosomal dominant optic atrophy. Acta Ophthalmol. 91, e413-e414 (2013).
89. Alexander, C. et al. OPA1, encoding a dynamin- related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat. Genet. 26, 211-215 (2000).
90. Delettre, C. et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat. Genet. 26, 207-210 (2000).
91. Ferre, M. et al. Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 novel OPA1 mutations. Hum. Mutat. 30, E692-E705 (2009).
92. Aijaz, S., Erskine, L., Jeffery, G., Bhattacharya, S. S. & Votruba, M. Developmental expression profile of the optic atrophy gene product: OPA1 is not localized exclusively in the mammalian retinal ganglion cell layer. Invest. Ophthalmol. Vis. Sci. 45, 1667-1673 (2004).
93. Bette, S., Schlaszus, H., Wissinger, B., Meyermann, R. & Mittelbronn, M. OPA1, associated with autosomal dominant optic atrophy, is widely expressed in the human brain. Acta Neuropathol. 109, 393-399 (2005).
94. Pesch, U. E. et al. OPA1, the disease gene for autosomal dominant optic atrophy, is specifically expressed in ganglion cells and intrinsic neurons of the retina. Invest. Ophthalmol. Vis. Sci. 45, 4217-4225 (2004).
95. Wang, A. G., Fann, M. J., Yu, H. Y. & Yen, M. Y. OPA1 expression in the human retina and optic nerve. Exp. Eye Res. 83, 1171-1178 (2006).
96. Marchbank, N. J. et al. Deletion of the OPA1 gene in a dominant optic atrophy family: evidence that haploinsufficiency is the cause of disease. J. Med. Genet. 39, e47 (2002).
97. Amati-Bonneau, P. et al. The association of autosomal dominant optic atrophy and moderate deafness may be due to the R445H mutation in the OPA1 gene. Am. J. Ophthalmol. 136, 1170-1171 (2003).
98. Leruez, S. et al. Sensorineural hearing loss in OPA1-linked disorders. Brain 136, e236 (2013).
99. Amati-Bonneau, P. et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy plus phenotypes. Brain 131, 338-351 (2008).
100. Hudson, G. et al. Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain 131, 329-337 (2008).
101. Spinazzi, M. et al. A novel deletion in the GTPase domain of OPA1 causes defects in mitochondrial morphology and distribution, but not in function. Hum. Mol. Genet. 17, 3291-3302 (2008).
102. Yu-Wai-Man, P. et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain 133, 771-786 (2010).
103. Pretegiani, E. et al. Spastic paraplegia in 'dominant optic atrophy plus' phenotype due to OPA1 mutation. Brain 134, e195 (2011).
104. Marelli, C. et al. Heterozygous OPA1 mutations in Behr syndrome. Brain 134, e169 (2011).
105. Liskova, P. et al. Novel OPA1 missense mutation in a family with optic atrophy and severe widespread neurological disorder. Acta Ophthalmol. 91, E225-E231 (2013).
106. Ranieri, M. et al. Optic atrophy plus phenotype due to mutations in the OPA1 gene: two more Italian families. J. Neurol. Sci. 315, 146-149 (2012).
107. Zuchner, S. et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat. Genet. 36, 449-451 (2004).
108. Feely, S. M. et al. MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology 76, 1690-1696 (2011).
109. Verhoeven, K. et al. MFN2 mutation distribution and genotype/phenotype correlation in Charcot- Marie-Tooth type 2. Brain 129, 2093-2102 (2006).
110. Zuchner, S. et al. Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann. Neurol. 59, 276-281 (2006).
111. Polke, J. M. et al. Recessive axonal Charcot- Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations. Neurology 77, 168-173 (2011).
112. Chen, H., McCaffery, J. M. & Chan, D. C. Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell 130, 548-562 (2007).
113. Chen, H. et al. Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. Cell 141, 280-289 (2010).
114. Larsson, N. G. et al. Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat. Genet. 18, 231-236 (1998).
115. Garrido, N. et al. Composition and dynamics of human mitochondrial nucleoids. Mol. Biol. Cell 14, 1583-1596 (2003).
116. Holt, I. J. et al. Mammalian mitochondrial nucleoids: organizing an independently minded genome. Mitochondrion 7, 311-321 (2007).
117. Kaufman, B. A. et al. The mitochondrial transcription factor TFAM coordinates the assembly of multiple DNA molecules into nucleoid-like structures. Mol. Biol. Cell 18, 3225-3236 (2007).
118. Hudson, G. & Chinnery, P. F. Mitochondrial DNA polymerase-ã and human disease. Hum. Mol. Genet. 15, R244-R252 (2006).
119. McFarland, R., Taylor, R. W. & Turnbull, D. M. A neurological perspective on mitochondrial disease. Lancet Neurol. 9, 829-840 (2010).
120. Schapira, A. H. Mitochondrial diseases. Lancet 379, 1825-1834 (2012).
121. Alberio, S., Mineri, R., Tiranti, V. & Zeviani, M. Depletion of mtDNA: syndromes and genes. Mitochondrion 7, 6-12 (2007).
122. th ENMC workshop: polymerase gamma and disorders of mitochondrial DNA synthesis, 21-23 September 2007, Naarden, The Netherlands. Neuromuscul. Disord. 18, 259-267 (2008).
123. Suomalainen, A. & Isohanni, P. Mitochondrial DNA depletion syndromes-many genes, common mechanisms. Neuromuscul. Disord. 20, 429-437 (2010).
124. Del Bo, R. et al. Remarkable infidelity of polymerase γA associated with mutations in POLG1 exonuclease domain. Neurology 61, 903-908 (2003).
125. Nishigaki, Y., Marti, R., Copeland, W. C. & Hirano, M. Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency. J. Clin. Invest. 111, 1913-1921 (2003).
126. Wanrooij, S. et al. Twinkle and POLG defects enhance age-dependent accumulation of mutations in the control region of mtDNA. Nucleic Acids Res. 32, 3053-3064 (2004).
127. Yu-Wai-Man, P. et al. OPA1 mutations cause cytochrome c oxidase deficiency due to loss of wild-type mtDNA molecules. Hum. Mol. Genet. 19, 3043-3052 (2010).
128. Durham, S. E., Samuels, D. C., Cree, L. M. & Chinnery, P. F. Normal levels of wild-type mitochondrial DNA maintain cytochrome c oxidase activity for two pathogenic mitochondrial DNA mutations but not for m.3243A→G. Am. J. Hum. Genet. 81, 189-195 (2007).
129. Koopman, W. J., Distelmaier, F., Smeitink, J. A. & Willems, P. H. OXPHOS mutations and neurodegeneration. EMBO J. 32, 9-29 (2013).
130. Taylor, R. W., Schaefer, A. M., Barron, M. J., McFarland, R. & Turnbull, D. M. The diagnosis of mitochondrial muscle disease. Neuromuscul. Disord. 14, 237-245 (2004).
131. Rouzier, C. et al. The MFN2 gene is responsible for mitochondrial DNA instability and optic atrophy 'plus' phenotype. Brain 135, 23-34 (2012).
132. Zeviani, M. OPA1 mutations and mitochondrial DNA damage: keeping the magic circle in shape. Brain 131, 314-317 (2008).
133. Vidoni, S., Zanna, C., Rugolo, M., Sarzi, E. & Lenaers, G. Why mitochondria must fuse to maintain their genome integrity. Antioxid. Redox Signal. 19, 379-388 (2013).
134. Stewart, J. D. et al. OPA1 in multiple mitochondrial DNA deletion disorders. Neurology 71, 1829-1831 (2008).
135. Elachouri, G. et al. OPA1 links human mitochondrial genome maintenance to mtDNA replication and distribution. Genome Res. 21, 12-20 (2011).
136. Payne, B. A. et al. Universal heteroplasmy of human mitochondrial DNA. Hum. Mol. Genet. 22, 384-390 (2013).
137. Sitarz, K. S. et al. OPA1 mutations induce mtDNA proliferation in leukocytes of patients with dominant optica atrophy. Neurology 79, 1515-1517 (2012).
138. Iommarini, L. et al. Revisiting the issue of mitochondrial DNA content in optic mitochondriopathies. Neurology 79, 1517-1519 (2012).
139. Sitarz, K. S. et al. MFN2 mutations cause compensatory mitochondrial DNA proliferation. Brain 135, e219 (2012).
140. Renaldo, F. et al. MFN2, a new gene responsible for mitochondrial DNA depletion. Brain 135, e223 (2012).
141. Yu-Wai-Man, P. & Chinnery, P. F. Dysfunctional mitochondrial maintenance: what breaks the circle of life? Brain 135, 9-11 (2012).
142. Salinas, S., Proukakis, C., Crosby, A. & Warner, T. T. Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol. 7, 1127-1138 (2008).
143. Blackstone, C., O'Kane, C. J. & Reid, E. Hereditary spastic paraplegias: membrane traffic and the motor pathway. Nat. Rev. Neurosci. 12, 31-42 (2011).
144. Timmerman, V., Clowes, V. E. & Reid, E. Overlapping molecular pathological themes link Charcot-Marie-Tooth neuropathies and hereditary spastic paraplegias. Exp. Neurol. 246, 14-25 (2013).
145. Harding, A. E. Classification of the hereditary ataxias and paraplegias. Lancet 1, 1151-1155 (1983).
146. Casari, G. et al. Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell 93, 973-983 (1998).
147. Ferreirinha, F. et al. Axonal degeneration in paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport. J. Clin. Invest. 113, 231-242 (2004).
148. Klebe, S. et al. Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy. Brain 135, 2980-2993 (2012).
149. van Gassen, K. L. et al. Genotype-phenotype correlations in spastic paraplegia type 7: a study in a large Dutch cohort. Brain 135, 2994-3004 (2012).
150. Greaves, L. C. et al. Mitochondrial DNA defects and selective extraocular muscle involvement in CPEO. Invest. Opthalmol. Vis. Sci. 51, 3340-3346 (2010).
151. Pfeffer, G. et al. Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance. Brain 137, 1323-1336 (2014).
152. Wedding, I. M. et al. Spastic paraplegia type 7 is associated with multiple mitochondrial DNA deletions. PLoS ONE 9, e86340 (2014).
153. Di Bella, D. et al. Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28. Nat. Genet. 42, 313-320 (2010).
154. Pierson, T. M. et al. Whole-exome sequencing identifies homozygous AFG3L2 mutations in a spastic ataxia-neuropathy syndrome linked to mitochondrial m-AAA proteases. PLoS Genet. 7, e1002325 (2011).
155. Maltecca, F. et al. Respiratory dysfunction by AFG3L2 deficiency causes decreased mitochondrial calcium uptake via organellar network fragmentation. Hum. Mol. Genet. 21, 3858-3870 (2012).
156. Almajan, E. R. et al. AFG3L2 supports mitochondrial protein synthesis and Purkinje cell survival. J. Clin. Invest. 122, 4048-4058 (2012).
157. Kondadi, A. K. et al. Loss of the m-AAA protease subunit AFG3L2 causes mitochondrial transport defects and tau hyperphosphorylation. EMBO J. 33, 1011-1026 (2014).
158. Nguyen, T. T. et al. Loss of Miro1-directed mitochondrial movement results in a novel murine model for neuron disease. Proc. Natl Acad. Sci. USA 111, E3631-E3640 (2014).
159. Paisan-Ruiz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600 (2004).
160. Macdonald, M. E. et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's-disease chromosomes. Cell 72, 971-983 (1993).
161. Engert, J. C. et al. ARSACS, a spastic ataxia common in northeastern Quebec, is caused by mutations in a new gene encoding an 11.5-kb ORF. Nat. Genet. 24, 120-125 (2000).
162. Costa, V. et al. Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Mol. Med. 2, 490-503 (2010).
163. Song, W. et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat. Med. 17, 377-382 (2011).
164. Girard, M. et al. Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). Proc. Natl Acad. Sci. USA 109, 1661-1666 (2012).
165. Wang, X. et al. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum. Mol. Genet. 21, 1931-1944 (2012).
166. Shirendeb, U. et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum. Mol. Genet. 20, 1438-1455 (2011).
167. Shirendeb, U. P. et al. Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. Hum. Mol. Genet. 21, 406-420 (2012).
168. Manczak, M., Calkins, M. J. & Reddy, P. H. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum. Mol. Genet. 20, 2495-2509 (2011).
169. Manczak, M. & Reddy, P. H. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum. Mol. Genet. 21, 2538-2547 (2012).
170. Calkins, M. J., Manczak, M., Mao, P., Shirendeb, U. & Reddy, P. H. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum. Mol. Genet. 20, 4515-4529 (2011).
171. Schon, E. A. & Area-Gomez, E. Mitochondria- associated ER membranes in Alzheimer disease. Mol. Cell. Neurosci. 55, 26-36 (2013).
172. Hedskog, L. et al. Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer's disease and related models. Proc. Natl Acad. Sci. USA 110, 7916-7921 (2013).
173. Bannwarth, S. et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain 137, 2329-2345 (2014).
174. Chaussenot, A. et al. Screening of CHCHD10 in a French cohort confirms the involvement of this gene in frontotemporal dementia with amyotrophic lateral sclerosis patients. Neurobiol. Aging 35, 2884.e1-2884.e4 (2014).
175. Yu-Wai-Man, P., Votruba, M., Moore, A. T. & Chinnery, P. F. Treatment strategies for inherited optic neuropathies: past, present and future. Eye (Lond.) 28, 527-537 (2014).
176. Yu-Wai-Man, P., Griffiths, P. G. & Chinnery, P. F. Mitochondrial optic neuropathies-disease mechanisms and therapeutic strategies. Prog. Retin. Eye Res. 30, 81-114 (2011).
177. Carelli, V., La Morgia, C. & Sadun, A. A. Mitochondrial dysfunction in optic neuropathies: animal models and therapeutic options. Curr. Opin. Neurol. 26, 52-58 (2013).
178. Chen, H. & Chan, D. C. Mitochondrial dynamics- fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum. Mol. Genet. 18, R169-R176 (2009).
179. Sarkar, S. et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol. 3, 331-338 (2007).
180. Bove, J., Martinez-Vicente, M. & Vila, M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat. Rev. Neurosci. 12, 437-452 (2011).
181. Harris, H. & Rubinsztein, D. C. Control of autophagy as a therapy for neurodegenerative disease. Nat. Rev. Neurol. 8, 108-117 (2012).
182. Man, P. Y., Turnbull, D. M. & Chinnery, P. F. Leber hereditary optic neuropathy. J. Med. Genet. 39, 162-169 (2002).
183. Klopstock, T. et al. A randomized placebo- controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 134, 2677-2686 (2011).
184. Carelli, V. et al. Idebenone treatment In Leber's hereditary optic neuropathy. Brain 134, e188 (2011).
185. Klopstock, T. et al. Persistence of the treatment effect of idebenone in Leber's hereditary optic neuropathy. Brain 136, e230 (2013).
186. Sadun, A. A. et al. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. Arch. Neurol. 69, 331-338 (2012).
187. Cipolat, S., de Brito, O. M., Dal Zilio, B. & Scorrano, L. OPA1 requires mitofusin 1 to promote mitochondrial fusion. Proc. Natl Acad. Sci. USA 101, 15927-15932 (2004).
188. MacAskill, A. F. et al. Miro1 is a calcium sensor for glutamate receptor-dependent localization of mitochondria at synapses. Neuron 61, 541-555 (2009).
189. Misko, A., Jiang, S., Wegorzewska, I., Milbrandt, J. & Baloh, R. H. Mitofusin 2 Is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. J. Neurosci. 30, 4232-4240 (2010).
190. Cassidy-Stone, A. et al. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev. Cell 14, 193-204 (2008).
191. Cereghetti, G. M., Costa, V. & Scorrano, L. Inhibition of Drp1-dependent mitochondrial fragmentation and apoptosis by a polypeptide antagonist of calcineurin. Cell Death Differ. 17, 1785-1794 (2010).
192. Iwasawa, R., Mahul-Mellier, A.-L., Datler, C., Pazarentzos, E. & Grimm, S. Fis1 and Bap31 bridge the mitochondria-ER interface to establish a platform for apoptosis induction. EMBO J. 30, 556-568 (2011).
193. Wells, T. et al. Opa3, a novel regulator of mitochondrial function, controls thermogenesis and abdominal fat mass in a mouse model for Costeff syndrome. Hum. Mol. Genet. 21, 4836-4844 (2012).
194. Huizing, M. et al. OPA3, mutated in 3-methylglutaconic aciduria type III, encodes two transcripts targeted primarily to mitochondria. Mol. Genet. Metab. 100, 149-154 (2010).
195. Ryu, S.-W., Jeong, H. J., Choi, M., Karbowski, M. & Choi, C. Optic atrophy 3 as a protein of the mitochondrial outer membrane induces mitochondrial fragmentation. Cell. Mol. Life Sci. 67, 2839-2850 (2010).
196. Niemann, A., Ruegg, M., La Padula, V., Schenone, A. & Suter, U. Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. J. Cell Biol. 170, 1067-1078 (2005).
197. Niemann, A., Wagner, K. M., Ruegg, M. & Suter, U. GDAP1 mutations differ in their effects on mitochondrial dynamics and apoptosis depending on the mode of inheritance. Neurobiol. Dis. 36, 509-520 (2009).
198. Claramunt, R. et al. Genetics of Charcot-Marie- Tooth disease type 4A: mutations, inheritance, phenotypic variability, and founder effect. J. Med. Genet. 42, 358-365 (2005).
199. Waterham, H. R. et al. A lethal defect of mitochondrial and peroxisomal fission. N. Engl. J.Med. 356, 1736-1741 (2007).
200. Chang, C.-R. et al. A lethal de novo mutation in the middle domain of the dynamin-related GTPase Drp1 impairs higher order assembly and mitochondrial division. J. Biol. Chem. 285, 32494-32503 (2010).
201. Reynier, P. et al. OPA3 gene mutations responsible for autosomal dominant optic atrophy and cataract. J. Med. Genet. 41, e110 (2004).
202. Baxter, R. V. et al. Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nat. Genet. 30, 21-22 (2002).
203. Anikster, Y., Kleta, R., Shaag, A., Gahl, W. A. & Elpeleg, O. Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews. Am. J. Hum. Genet. 69, 1218-1224 (2001).
204. Yarosh, W. et al. The molecular mechanisms of OPA1-mediated optic atrophy in Drosophila model and prospects for antioxidant treatment. PLoS Genet. 4, e6 (2008).
205. Tang, S., Le, P. K., Tse, S., Wallace, D. C. & Huang, T. Heterozygous mutation of Opa1 in Drosophila shortens lifespan mediated through increased reactive oxygen species production. PLoS ONE 4, e4492 (2009).
206. Shahrestani, P. et al. Heterozygous mutation of Drosophila Opa1 causes the development of multiple organ abnormalities in an age- dependent and organ-specific manner. PLoS ONE 4, e6867 (2009).
207. Rahn, J. J., Stackley, K. D. & Chan, S. S. Opa1 is required for proper mitochondrial metabolism in early development. PLoS ONE 8, e59218 (2013).
208. Davies, V. J. et al. Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function. Hum. Mol. Genet. 16, 1307-1318 (2007).
209. Alavi, M. V. et al. A splice site mutation in the murine Opa1 gene features pathology of autosomal dominant optic atrophy. Brain 130, 1029-1042 (2007).
210. Alavi, M. V. et al. Subtle neurological and metabolic abnormalities in an Opa1 mouse model of autosomal dominant optic atrophy. Exp. Neurol. 220, 404-409 (2009).
211. Moore, B. A., Aviles, G. D., Larkins, C. E., Hillman, M. J. & Caspary, T. Mitochondrial retention of Opa1 is required for mouse embryogenesis. Mamm. Gen. 21, 350-360 (2010).
212. delTTAG mutation induces premature age-related systemic neurodegeneration in mouse. Brain 135, 3599-3613 (2012).
213. Williams, P. A., Morgan, J. E. & Votruba, M. Opa1 deficiency in a mouse model of dominant optic atrophy leads to retinal ganglion cell dendropathy. Brain 133, 2942-2951 (2010).
214. Williams, P. A. et al. Opa1 is essential for retinal ganglion cell synaptic architecture and connectivity. Brain 135, 493-505 (2012).
215. Yu-Wai-Man, P. et al. Secondary mtDNA defects do not cause optic nerve dysfunction in a mouse model of dominant optic atropy. Invest. Opthalmol. Vis. Sci. 50, 4561-4566 (2009).
216. 2+ crosstalk. Circ. Res. 111, 863-875 (2012).
217. nd et al. MARF and Opa1 control mitochondrial and cardiac function in Drosophila. Circ. Res. 108, 12-17 (2011).
218. Eschenbacher, W. H. et al. Two rare human mitofusin 2 mutations alter mitochondrial dynamics and induce retinal and cardiac pathology in Drosophila. PLoS ONE 7, e44296 (2012).
219. Deng, H., Dodson, M. W., Huang, H. & Guo, M. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc. Natl Acad. Sci. USA 105, 14503-14508 (2008).
220. Chapman, A. L., Bennett, E. J., Ramesh, T. M., De Vos, K. J. & Grierson, A. J. Axonal transport defects in a mitofusin 2 loss of function model of Charcot-Marie-Tooth disease in zebrafish. PLoS ONE 8, e67276 (2013).
221. Vettori, A. et al. Developmental defects and neuromuscular alterations due to mitofusin 2 gene (MFN2) silencing in zebrafish: a new model for Charcot-Marie-Tooth type 2A neuropathy. Neuromuscul. Disord. 21, 58-67 (2011).
222. Chen, L. et al. OPA1 mutation and late-onset cardiomyopathy: mitochondrial dysfunction and mtDNA instability. J. Am. Heart Assoc. 1, e003012 (2012).
223. Lee, S. et al. Mitofusin 2 is necessary for striatal axonal projections of midbrain dopamine neurons. Hum. Mol. Genet. 21, 4827-4835 (2012).
224. Pham, A. H., Meng, S., Chu, Q. N. & Chan, D. C. Loss of Mfn2 results in progressive, retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit. Hum. Mol. Genet. 21, 4817-4826 (2012).
225. Detmer, S. A., Velde, C. V., Cleveland, D. W. & Chan, D. C. Hindlimb gait defects due to motor axon loss and reduced distal muscles in a transgenic mouse model of Charcot-Marie- Tooth type 2A. Hum. Mol. Genet. 17, 367-375 (2008).
226. Cartoni, R. et al. Expression of mitofusin 2(R94Q) in a transgenic mouse leads to Charcot-Marie-Tooth neuropathy type 2A. Brain 133, 1460-1469 (2010).
227. ATP channel opening in a mouse model carrying a mitofusin 2 mutation. FASEB J. 25, 1618-1627 (2011).